Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

UCB presenting data on osteoporosis and romosozumab at 2015 American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Brussels, Belgium, 8th October, 2015 - UCB today announced that it will present data from multiple studies for investigational molecule romosozumab at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Seattle on Oct. 9-12, 2015. In addition, osteoporosis disease-state presentations will provide key insights around unmet needs among patients at high risk for fracture, and the potentially serious consequences of inadequate osteoporosis treatment.

“Data to be presented at ASBMR 2015 include some of the latest research on our investigational medicine romosozumab,” said Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President, UCB. “Our previous studies have shown that romosozumab stimulates bone formation and reduces bone resorption making it different from most available current treatments for osteoporosis. The data presented at ASBMR give us further confidence that romosozumab has the potential to become a novel treatment for people with osteoporosis.”

Romosozumab is being co-developed by UCB and Amgen.

The following is a guide to the UCB/Amgen sponsored data presentations.

Romosozumab Oral Presentations

  • Romosozumab Improves Strength at the Lumbar Spine and Hip in Postmenopausal Women With Low Bone Mass Compared With Teriparatide, Abstract 1143, Oral Presentation, Monday, October 12, 10:30 a.m.-10:45 a.m. PT (Room 6E)
  • Romosozumab (Sclerostin Antibody) Improves Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys After 12 Months of Treatment, Abstract 1019, Oral Presentation, Friday, October 9, 2:00 p.m.-2:15 p.m. PT (Room 6E)

Romosozumab Abstracts of Interest

  • Effects of Romosozumab in Japanese Women With Postmenopausal Osteoporosis: Phase 2 Trial Results, Abstracts FR0331 and SA0331, Poster Presentation, Friday, October 9, 5:30pm - 7:30pm and Saturday October 10, 12:30pm – 2:30pm (Hall 4B)
  • Analysis of the Osteoblast Lineage Reveals Inhibition of Mitogenesis and Cell Cycle Progression Associated With Attenuation of Bone Formation in Response to Sclerostin Antibody in Ovariectomized Rats, Abstract MO0193, Poster Presentation, Monday, October 12, 12:30pm – 2:30pm (Hall 4B)
  • Stereological Analysis Reveals Differential Effects of Sclerostin Antibody and Parathyroid Hormone on the Osteoblast Lineage in Young Female Rats, Abstract MO0154, Poster Presentation, Monday, October 12, 12:30pm – 2:30pm (Hall 4B)

Osteoporosis Disease State Oral Presentation

  • Predicting Imminent Risk for Fracture in Patients With Osteoporosis Using Commercially Insured Claims Data, Abstract 1066, Oral Presentation, Saturday, October 10, 5:15 p.m.-5:30 p.m. PT (Room 6B)

Osteoporosis Disease State Abstracts of Interest

  • Change in Physical Function Following Hip Fracture Among Elderly Osteoporotic Women, Abstract MO0307, Poster Presentation, Monday, October 12, 12:30pm – 2:30pm (Hall 4B)
  • Predictors of Imminent Fracture Risk in Women Aged ≥65 Years With Osteoporosis, Abstract SA0282, Poster Presentation, Saturday, October 10, 12:30pm – 2:30pm (Hall 4B)
  • Imminent Fracture Risk in Elderly Osteoporotic Women: Underlying Relationships Between Risk Factors and Outcome, Abstract MO0292, Poster Presentation, Monday, October 12, 12:30pm – 2:30pm (Hall 4B)
  • Utilization of Osteoporosis Medication After a Fragility Fracture Among Elderly Medicare Beneficiaries, Abstract MO0350, Poster Presentation, Monday, October 12, 12:30pm – 2:30pm (Hall 4B)
  • Hospitalizations for Osteoporosis-Related Fractures: Economic Cost and Clinical Outcomes, Abstract SA0302, Poster Presentation, Saturday, October 10, 12:30pm – 2:30pm (Hall 4B)
  • Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women, Abstract SA0292, Poster Presentation, Saturday, October 10, 12:30pm – 2:30pm (Hall 4B)

About Romosozumab
Romosozumab is an investigational bone-forming agent and is not approved by any regulatory authority for the treatment of osteoporosis. It is designed to work by inhibiting the protein sclerostin, thereby increasing bone formation and decreasing bone breakdown.  Romosozumab is being studied for its potential to reduce the risk of fractures in an extensive global Phase 3 program. This program includes two large fracture trials comparing romosozumab to either placebo or active comparator in more than 10,000 postmenopausal women with osteoporosis. First results from the Phase 3 study FRAME are expected in H1 2016. Romosozumab is being co-developed by Amgen and UCB.

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Forward looking statements – UCB
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.  UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

For further Information
France Nivelle, Global Communications, UCB
T +32.2.559.9178, france.nivelle@ucb.com
Laurent Schots, Media Relations, UCB
T+32.2.559.92.64, Laurent.schots@ucb.com
Antje Witte, Investor Relations, UCB
T +32.2.559.94.14, antje.witte@ucb.com
Scott Fleming, Communications Director, Bone, UCB
T +447702777378, scott.fleming@ucb.com
 

 


Stay up-to-date on the latest news and information from UCB